The UK registration of ColoAlert gives Mainz Biomed (MNB) its first foothold in one of Europe’s largest health‑care markets and removes a key regulatory hurdle that had previously limited commercial rollout. Management is likely to incorporate the new market opportunity into its 2025‑2026 revenue model, projecting incremental sales of roughly €4‑6 m per year once the test is reimbursed by the NHS. That modest but meaningful top‑line lift should be enough to nudge the company’s 2025 revenue outlook upward by 5‑7 % and could prompt a modest upgrade to its earnings‑per‑share guidance, especially if the firm can accelerate distribution through its existing UK partner network.
From a technical standpoint, MNB has been trading near the 20‑day EMA (≈ $3.45) with RSI hovering around 55, indicating room for upside without being overbought. The news sparked a ~8 % intraday rally and broke through a short‑term resistance band at $3.55, suggesting the market is pricing in the near‑term revenue boost. Traders could consider entering on a pull‑back to the $3.40‑$3.45 range, targeting the next resistance near $3.80 (the 50‑day EMA) and placing a stop just below the $3.30 support level. Keep an eye on any further guidance updates in the upcoming Q3 earnings release and on NHS reimbursement negotiations, which remain the primary upside risk to the valuation.